<DOC>
	<DOCNO>NCT00327990</DOCNO>
	<brief_summary>This two part study ( screen treatment ) . The first part ( screen ) design evaluate percentage patient miss diagnose osteoporosis general practitioner ( GP 's ) . The second part ( treatment ) design determine preference patient monthly ibandronate weekly alendronate .</brief_summary>
	<brief_title>Evaluation Of Missed Osteoporosis Diagnoses , And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate</brief_title>
	<detailed_description>A multi-centre , randomised , open-label , cross-over study evaluate percentage false negative osteoporosis diagnosis use standard case-finding procedure describe Dutch Institute Health Care ( CBO ) determine preference adult osteoporosis patient monthly dose ibandronate ( 150 mg ) weekly dose alendronate ( 70 mg ) .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women register GP , without prior history osteoporosis . According casefinding procedure , osteoporosis diagnose exclude . Exclusion criterion : Abnormalities esophagus delay esophageal empty stricture achalasia . Inability stand sit upright position 60 minute . Previous use bone active agent ( e.g . strontium , PTH ) . Significant medical condition may preclude patient 's ability complete study . History alcohol drug abuse . Hypersensitivity component bisphosphonates alendronate ibandronate . Administration investigational drug within 30 day precede first dose study drug . Serum total calcium &gt; 10.5 mg/dL &lt; 8.0 mg/dL ( equivalent 2.63 mmol/L 1.99 mmol/L ) . Osteoporosis secondary cause , exclude especially isolated deformity vertebral body detect xray analysis .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ibandronate</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>preference</keyword>
	<keyword>case-finding</keyword>
	<keyword>post-menopausal</keyword>
	<keyword>alendronate</keyword>
</DOC>